Development and Initial Testing of a Modified UroVysion-Based Fluorescence In Situ Hybridization Score for Prediction of Progression in Bladder Cancer.

Development and Initial Testing of a Modified UroVysion-Based Fluorescence In Situ Hybridization Score for Prediction of Progression in Bladder Cancer. Am J Clin Pathol. 2019 Nov 16;: Authors: Kocsmár I, Pajor G, Gyöngyösi B, Székely E, Varga M, Kocsmár É, Kenessey I, Beöthe T, Süle N, Majoros A, Szendrői A, Nyírády P, Kiss A, Riesz P, Gábor L Abstract OBJECTIVES: Our aim was to predict progression of non-muscle-invasive bladder urothelial carcinomas (NMIUCs) into muscle-invasive disease by assessing cytogenetic abnormality of tumors with a new UroVysion scoring system. METHODS: Seventy-five bladder cancer cases (including 57 NMIUCs) were classified according to the quantitatively assessed degree of UroVysion-detected chromosomal abnormalities into urine fluorescence in situ hybridization score (UFS) groups: UFS I, II, and III. Cox time-to-event, Kaplan-Meier, and C-statistics analyses were performed. RESULTS: UFS proved to be an independent prognostic factor of progression-free survival (PFS) and time to progression (TTP). NMIUCs with UFS III had a 34.05-fold increased hazard for progression to muscle-invasive cancer (TTP; 95% confidence interval, 5.841-198.5; P
Source: American Journal of Clinical Pathology - Category: Pathology Authors: Tags: Am J Clin Pathol Source Type: research

Related Links:

In this study, our aim was to investigate the role of circular RNA on the hypoxic adaptive response in bladder cancer. Here, we identified a hypoxia-inducible circular RNA, has-circRNA-403658 that contributes to bladder cancer progression. Has-circRNA-403658 is spliced from its host gene, ZNF292, through back-splicing between the 1st and 4th exon. We demonstrated that has-circRNA-403658 was an important circRNA that upregulated in bladder cancer cells under hypoxia, and higher has-circRNA-403658 levels were associated with poorer survival outcome. Silencing has-circRNA-403658 in bladder cancer cells inhibited cell growth a...
Source: American Journal of Translational Research - Category: Research Tags: Am J Transl Res Source Type: research
AbstractThe treatment landscape for locally advanced or metastatic urothelial carcinoma has broadened significantly over recent years. New therapeutic options include immunotherapy with checkpoint inhibitors and targeted therapy with erdafitinib. Despite these advances, gaps remain in the selection and sequencing of optimal therapies. Treatment decisions are often influenced by several patient-specific factors such as tolerability and biomarker expression. Following progression while receiving front- and second-line therapies, there is no widely accepted standard of care for patients. Enrollment into a clinical trial is re...
Source: Drugs - Category: Drugs & Pharmacology Source Type: research
Conclusion.The multimodal treatment consisted of a maximal TUR‐BT followed by RT; concomitant platinum‐based chemotherapy combined with RHT in patients with high‐grade bladder cancer improves local control, bladder‐preservation rate, and OS. It offers a promising alternative to surgical therapies like radical cystectomy.Implications for Practice.Radical cystectomy with appropriate lymph node dissection has long represented the standard of care for muscle‐invasive bladder cancer in medically fit patients, despite many centers reporting excellent long‐term results for bladder preserving strategies. This retrospec...
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Radiation Oncology, Genitourinary Cancer Source Type: research
ConclusionIndiana pouch is a successful continence urinary reservoir with a reproductible technique, however long-term observation is needed.
Source: International Journal of Surgery Case Reports - Category: Surgery Source Type: research
On the basis of some significant clinical parameters, we had an intent to establish nomograms for estimating the prognosis of patients with squamous cell carcinoma of the urinary bladder (SCCB), including over...
Source: BMC Cancer - Category: Cancer & Oncology Authors: Tags: Research article Source Type: research
Urothelial carcinoma (UC) is the most common malignant neoplasm of the bladder that encompasses a wide spectrum of histopathologic features and various molecular alterations and subtypes, responsible for its significant morphologic and genomic heterogeneity. Morphologically, in addition to classic UC (not otherwise specified), many well documented variant histologies are a common finding in invasive UC, and include squamous, glandular, micropapillary, sarcomatoid, small cell/neuroendocrine, clear cell, lymphoepithelioma-like, and plasmacytoid types, among others. This review provides an update on the recent advances in the...
Source: Advances in Anatomic Pathology - Category: Pathology Tags: Review Articles Source Type: research
lncRNA AWPPH promotes the migration and invasion of glioma cells by activating the TGF-β pathway. Oncol Lett. 2019 Dec;18(6):5923-5929 Authors: Dai B, Xiao Z, Mao B, Zhu G, Huang H, Guan F, Su H, Lin Z, Peng W, Hu Z Abstract The long noncoding RNA (lncRNA) AWPPH, also termed microRNA-4435-2HG, has been associated with the poor prognosis of patients with hepatocellular carcinoma (HCC), and has been demonstrated to promote the progression of HCC and bladder cancer. The present study aimed to investigate the role of lncRNA AWPPH in glioma. The expression levels of AWPPH in tumor tissues obtained from...
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
Authors: Qi Z, Yuan L, Sun N Abstract 2,6-diisopropylphenol (propofol) is a commonly used intravenous anesthetic drug, which has been reported to serve an antitumor role in human cancers. The current study aimed to assess the effects of propofol on the biological behaviors of human bladder cancer cells and to elucidate its potential molecular mechanism. The results of MTT, wound healing and Matrigel invasion assays demonstrated that propofol significantly inhibited the viability, migration and invasion of bladder cancer T24 cells in vitro. Reverse transcription-quantitative PCR and western blotting revealed that pr...
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
BALVERSA is a drug for the treatment of a type of bladder and urinary tract cancer called urothelial carcinoma. BALVERSA may be used in patients with urothelial carcinoma: whose tumors have a certain type of abnormal (FGFR) gene and whose cancer has spread (locally advanced or metastatic urothelial
Source: FDA Center for Drug Evaluation and Research - What's New - Category: Drugs & Pharmacology Authors: Source Type: news
This study will enhance our understanding of the molecular mechanism of UBC and may eventually provide novel targets for individualized cancer therapy. PMID: 31800162 [PubMed - as supplied by publisher]
Source: J Cell Mol Med - Category: Molecular Biology Authors: Tags: J Cell Mol Med Source Type: research
More News: Bladder Cancer | Cancer | Cancer & Oncology | Carcinoma | Pathology | Statistics